The biotech firm, trading under the ticker DCOY, noted that the five-year expiration window for these instruments remains in effect as previously announced. The correction addresses an error in the original September 22 statement, which had incorrectly suggested that the warrants were contingent upon a shareholder vote. All other details surrounding the transaction remain unchanged according to the company’s updated filing.
Decoy Therapeutics Corrects Terms of Recent Warrant Inducement Deal
Houston-based Decoy Therapeutics issued a formal correction Monday regarding the terms of its latest warrant inducement transaction. The company clarified that the new unregistered warrants, covering up to 2,368,868 shares of common stock, do not require stockholder approval and will become exercisable immediately upon their issuance.
Comments (0)
No comments yet. Be the first!